These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33812245)

  • 21. The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.
    Al-Hakeim HK; Almulla AF; Maes M
    Neurotox Res; 2020 Mar; 37(3):753-771. PubMed ID: 31916129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis.
    Kanchanatawan B; Sriswasdi S; Thika S; Stoyanov D; Sirivichayakul S; Carvalho AF; Geffard M; Maes M
    J Eval Clin Pract; 2018 Aug; 24(4):879-891. PubMed ID: 29790237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients.
    Sirivichayakul S; Kanchanatawan B; Thika S; Carvalho AF; Maes M
    Neurotox Res; 2019 Jan; 35(1):122-138. PubMed ID: 30056534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: a Nomothetic Network Psychiatry Approach.
    Maes M; Sirivichayakul S; Matsumoto AK; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Barbosa DS; Carvalho AF; Solmi M; Kanchanatawan B
    Mol Neurobiol; 2020 Nov; 57(11):4578-4597. PubMed ID: 32754898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathway Phenotypes Underpinning Depression, Anxiety, and Chronic Fatigue Symptoms Due to Acute Rheumatoid Arthritis: A Precision Nomothetic Psychiatry Analysis.
    Smesam HN; Qazmooz HA; Khayoon SQ; Almulla AF; Al-Hakeim HK; Maes M
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity.
    Maes M; Almulla AF; Zhou B; Algon AAA; Sodsai P
    Sci Rep; 2024 Mar; 14(1):7344. PubMed ID: 38538641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs.
    Kanchanatawan B; Sirivichayakul S; Carvalho AF; Anderson G; Galecki P; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):205-216. PubMed ID: 28690204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in individuals with attenuated psychotic symptoms: Possible role of anxiety, depressive symptoms, and socio-cognitive impairments.
    Takahashi T; Higuchi Y; Komori Y; Nishiyama S; Nakamura M; Sasabayashi D; Nishikawa Y; Sumiyoshi T; Suzuki M
    Psychiatry Res; 2017 Nov; 257():431-437. PubMed ID: 28837932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.
    Kanchanatawan B; Maes M
    CNS Neurol Disord Drug Targets; 2018; 17(6):473-486. PubMed ID: 29968545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic approach.
    Al-Hadrawi DS; Al-Rubaye HT; Almulla AF; Al-Hakeim HK; Maes M
    Acta Neuropsychiatr; 2023 Apr; 35(2):76-87. PubMed ID: 36134517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Research and Diagnostic Algorithmic Rules (RADAR) and RADAR Plots for the First Episode of Major Depressive Disorder: Effects of Childhood and Recent Adverse Experiences on Suicidal Behaviors, Neurocognition and Phenome Features.
    Maes M; Almulla AF
    Brain Sci; 2023 Apr; 13(5):. PubMed ID: 37239186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome.
    Al-Musawi AF; Al-Hakeim HK; Al-Khfaji ZA; Al-Haboby IH; Almulla AF; Stoyanov DS; Maes M
    Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of comorbid anxiety symptoms on cognitive deficits in patients with major depressive disorder.
    Liu J; Dong Q; Lu X; Sun J; Zhang L; Wang M; Liu B; Ju Y; Wan P; Guo H; Zhao F; Zhang X; Zhang Y; Li L
    J Affect Disord; 2020 Jan; 260():91-96. PubMed ID: 31493645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to Construct a Bottom-Up Nomothetic Network Model and Disclose Novel Nosological Classes by Integrating Risk Resilience and Adverse Outcome Pathways with the Phenome of Schizophrenia.
    Maes M; Vojdani A; Galecki P; Kanchanatawan B
    Brain Sci; 2020 Sep; 10(9):. PubMed ID: 32957709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.
    Kanchanatawan B; Sirivichayakul S; Thika S; Ruxrungtham K; Carvalho AF; Geffard M; Anderson G; Noto C; Ivanova R; Maes M
    Metab Brain Dis; 2017 Aug; 32(4):1003-1016. PubMed ID: 28258445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior.
    Kim CH; Jayathilake K; Meltzer HY
    Schizophr Res; 2003 Mar; 60(1):71-80. PubMed ID: 12505140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.
    Emsley RA; Oosthuizen PP; Joubert AF; Roberts MC; Stein DJ
    J Clin Psychiatry; 1999 Nov; 60(11):747-51. PubMed ID: 10584762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium.
    Al-Hakeim HK; Al-Naqeeb TH; Almulla AF; Maes M
    J Affect Disord; 2023 Jun; 331():300-312. PubMed ID: 36996718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
    Yoo I; Woo JM; Lee SH; Fava M; Mischoulon D; Papakostas GI; Kim EJ; Chung S; Ha JH; Jeon HJ
    J Affect Disord; 2015 Oct; 185():24-30. PubMed ID: 26142691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.